K. Serraj, Z. Ismaili, K. Bouhafs, M. Lehraiki, M. Mecili et al., Anémies ferriprives: de la physiopathologie à la clinique? Médecine Thérapeutique, vol.19, pp.10-20, 2013.

C. Camaschella, Iron-Deficiency Anemia. Longo DL, éditeur, N Engl J Med. 7 mai, vol.372, pp.1832-1875, 2015.
URL : https://hal.archives-ouvertes.fr/hal-00552375

A. Lopez, P. Cacoub, and I. C. Macdougall, Peyrin-Biroulet L. Iron deficiency anaemia, The Lancet. févr, vol.387, pp.907-923, 2016.

, Ministère des affaires sociales et de la santé, DGOS, 2014.

D. Sur,

F. Bauduer, Anémie par troubles du métabolisme du fer.pdf. EMC -Hématologie, 2009.

P. Brissot, . Métabolisme, and . Fer, Endocrinol-Nutr, vol.12, issue.4, 2015.

D. Sur,

G. Nicolas, C. Chauvet, L. Viatte, J. L. Danan, X. Bigard et al., The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation, J Clin Invest, vol.110, issue.7, pp.1037-1081, 2002.

G. Weiss, Anemia of Chronic Disease, N Engl J Med, vol.352, p.13, 2005.

F. Bauduer, Anémies inflammatoires et anémies des maladies chroniques, Encycl Méd Chir, 1999.

N. Anaemias-wsg-on and W. H. Organization, Nutritional anaemias : report of a WHO scientific group, 1967.

D. Sur, HAS -Rapport d'évaluation -Choix des examens du métabolisme du fer.pdf. HAS, 2011.

P. Dieusaert and . Medicales,

F. Blondé-cynober, Intérêt du dosage du récepteur solube de la transferrine dans le diagnostic biologique précoce du déficit martial chez les patients agés hospitalisés, Ann Biol Clin (Paris), vol.68, issue.5, pp.569-75, 2010.

G. Gavazzi, Iron metabolism: pathophysiology and biomarkers in elderly population

, Gériatrie Psychol Neuropsychiatr Viellissement. juin, issue.S2, pp.5-10, 2014.

E. Klein and . Erythopoïétine, Quand la prescrire ? Pourquoi et comment la doser ?, Ann Biol Clin (Paris), vol.67, issue.5, pp.505-215, 2009.

N. J. Kassebaum, R. Jasrasaria, M. Naghavi, S. K. Wulf, N. Johns et al., Situation nutritionnelle en France en 2006 selon les indicateurs d'objectif et les repères 76 du Programme national nutrition santé (PNNS). INVS, Blood, vol.123, issue.5, pp.615-624, 2006.

M. C. Weijmer, Preliminary report furunculosis and hypoferraemia, Lancet, issue.336, pp.464-470

G. S. Tansarli, D. E. Karageorgopoulos, A. Kapaskelis, I. Gkegkes, and M. E. Falagas, Iron deficiency and susceptibility to infections: evaluation of the clinical evidence, Eur J Clin Microbiol Infect Dis, vol.32, issue.10, pp.1253-1261, 2013.

A. Bourgarit-durand, Anémie ferriprives et ou inflammatoire, Rev Médecine Interne. 26 avr, pp.22-25, 2014.

P. Brunet, V. Faure, S. Burtey, H. Sichez, and Y. Berland, Anémie de l'insuffisance rénale chronique, EMC -Néphrologie. janv, vol.1, issue.1, pp.1-12, 2006.

J. Rottembourg, Utilisation des dérivés injectables du fer au cours de la maladie rénale chronique intérêt, limites et conseils de bon usage, Néphrologie Thérapeutique, 2015.

A. Aksan, H. I??k, H. H. Radeke, A. Dignass, and J. Stein, Systematic review with network metaanalysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease, Aliment Pharmacol Ther. mai, vol.45, issue.10, pp.1303-1321, 2017.

O. Nielsen, C. Soendergaard, M. Vikner, and G. Weiss, Rational Management of IronDeficiency Anaemia in Inflammatory Bowel Disease, Nutrients. 13 janv, vol.10, issue.1, p.82, 2018.

C. Gasche, A. Berstad, R. Befrits, C. Beglinger, A. Dignass et al., Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases#, Inflamm Bowel Dis. déc, vol.13, issue.12, pp.1545-53, 2007.

S. Kaitha, M. Bashir, and T. Ali, Iron deficiency anemia in inflammatory bowel disease, World J Gastrointest Pathophysiol, vol.6, issue.3, p.62, 2015.

L. T. Pizzi, C. M. Weston, N. I. Goldfarb, D. Moretti, N. Cobb et al., Impact of chronic conditions on quality of life in patients with inflammatory bowel disease, Inflamm Bowel Dis. janv, vol.12, issue.1, pp.47-52, 2006.

P. Ponikowski, D. J. Van-veldhuisen, J. Comin-colet, G. Ertl, M. Komajda et al., Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency, Eur Heart J. 1 mars, vol.36, issue.11, pp.657-68, 2015.

M. Borgeaud and A. Perrier, Carence en fer : une nouvelle cible thérapeutique dans l'insuffisance cardiaque ?

. Revue-médicale-suisse,

D. Sur,

A. Cohen-solal, C. Leclercq, G. Deray, S. Lasocki, J. Zambrowski et al., Iron deficiency: an emerging therapeutic target in heart failure, Heart. 15 sept, vol.100, issue.18, pp.1414-1434, 2014.

K. Ijt, J. Comin-colet, A. A. Voors, P. Ponikowski, C. Enjuanes et al., Iron deficiency in chronic heart failure: An international pooled analysis, Am Heart J. avr, vol.165, issue.4, pp.575-582, 2013.

E. A. Jankowska, P. Rozentryt, A. Witkowska, J. Nowak, O. Hartmann et al., Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure, J Card Fail, vol.17, issue.11, pp.899-906, 2011.

J. Comín-colet, C. Enjuanes, G. González, A. Torrens, M. Cladellas et al., Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status, Eur J Heart Fail, vol.15, issue.10, pp.659-69, 2013.

K. Knight, S. Wade, and L. Balducci, Prevalence and outcomes of anemia in cancer: a systematic review of the literature, Am J Med. avr, vol.116, issue.7, pp.11-26, 2004.

M. Hedenus and G. Birgegård, The role of iron supplementation during epoietin treatment for cancer-related anemia, Med Oncol. mars, vol.26, issue.1, pp.105-120, 2009.

F. A. Naoum, Iron deficiency in cancer patients. Rev Bras Hematol E Hemoter, vol.38, pp.325-355, 2016.

J. A. Gilreath, D. D. Stenehjem, and G. M. Rodgers, Diagnosis and treatment of cancer-related anemia: Diagnosis and treatment of cancer-related anemia, Am J Hematol. févr, vol.89, issue.2, pp.203-215, 2014.

J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella et al., Mechanisms of Cancer-Related Fatigue, The Oncologist. 1 mai, vol.12, issue.suppl_1, pp.22-34, 2007.

G. H. Lyman, E. R. Berndt, J. D. Kallich, M. H. Erder, W. H. Crown et al., The Economic Burden of Anemia in Cancer Patients Receiving Chemotherapy, Value Health. mars, vol.8, issue.2, pp.149-56, 2005.

E. Luporsi, L. Mahi, C. Morre, J. Wernli, G. De-pouvourville et al., Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesisstimulating agents and blood transfusion: French healthcare payer perspective, J Med Econ. janv, vol.15, issue.2, pp.225-257, 2012.

. Netgen, L'anémie du sujet âgé : une pathologie fréquente à ne pas banaliser

. Revue-médicale-suisse,

D. Sur, Izaks GJ. The Definition of Anemia in Older Persons, JAMA. 12 mai, vol.281, issue.18, p.1714, 1999.

B. F. Culleton, Impact of anemia on hospitalization and mortality in older adults, Blood. 15 mai, vol.107, issue.10, pp.3841-3847, 2006.

M. Ruivard, Anémie ferriprive chez l'adulte : diagnostic et traitement, Nutr Clin Métabolisme. 13 mars, issue.31, pp.104-110, 2017.

G. Beucher, E. Grossetti, T. Simonet, M. Leporrier, and M. Dreyfus, Anémie par carence martiale et grossesse. Prévention et traitement, J Gynécologie Obstétrique Biol Reprod. mai, vol.40, issue.3, pp.185-200, 2011.

J. Calop and S. Limat, Pharmacie Clinique et Thérapeutique. 4ème édition

J. Arlet, J. Pouchot, S. Lasocki, C. Beaumont, and O. Hermine, Supplémentation en fer : indications, limites et modalités, Rev Médecine Interne. janv, vol.34, issue.1, pp.26-31, 2013.

S. Schrier, Treatment of iron deficiency anemia in adults

. Uptodate, , 2018.

, Disponible sur: www.uptodate, p.51

T. Lee, T. Clavel, K. Smirnov, A. Schmidt, I. Lagkouvardos et al., Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD, Gut. mai, vol.66, issue.5, pp.863-71, 2017.

M. Auerbach and T. Deloughery, Single-dose intravenous iron for iron deficiency: a new paradigm, Hematology. 1 déc, vol.2016, issue.1, pp.57-66, 2016.

, Recommandation de bonne pratique -Transfusion de globules rouges homologues. HAS, 2014.

K. Hirano, Blood transfusion increases radical promoting non-transferrin bound iron in preterm infants, Arch Dis Child -Fetal Neonatal Ed. 1 mai, vol.84, issue.3, pp.188-193, 2001.

E. A. Hod, G. M. Brittenham, G. B. Billote, R. O. Francis, Y. Z. Ginzburg et al., Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron, Blood. 15 déc, vol.118, issue.25, pp.6675-82, 2011.

S. J. Taler, R. Agarwal, G. L. Bakris, J. T. Flynn, P. M. Nilsson et al., KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD, Am J Kidney Dis, vol.62, issue.2, pp.201-213, 2013.

I. C. Macdougall, A. J. Bircher, K. Eckardt, G. T. Obrador, C. A. Pollock et al., Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference, Kidney Int. janv, vol.89, issue.1, pp.28-39, 2016.

B. Rozen-zvi, A. Gafter-gvili, M. Paul, L. Leibovici, O. Shpilberg et al., Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: Systematic Review and Meta-analysis, Am J Kidney Dis, vol.52, issue.5, pp.897-906, 2008.

D. Shepshelovich, B. Rozen-zvi, T. Avni, U. Gafter, and A. Gafter-gvili, Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis, Am J Kidney Dis, vol.68, issue.5, pp.677-90, 2016.

A. U. Dignass, C. Gasche, D. Bettenworth, G. Birgegard, S. Danese et al.,

, European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases, J Crohns Colitis. 1 mars, vol.9, issue.3, pp.211-233, 2015.

P. Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J. Cleland et al., , 2016.

, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J. 14 juill, vol.37, issue.27, pp.2129-200, 2016.

S. D. Anker, C. Colet, J. Filippatos, G. Willenheimer, R. Dickstein et al., Ferric carboxymaltose in patients with heart failure and iron deficiency, N Engl J Med, vol.361, issue.25, pp.2436-2448, 2009.

J. D. Rizzo, M. Brouwers, P. Hurley, M. R. Somerfield, and S. Temin, of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer, J Oncol Pract, vol.6, issue.6, p.5, 2010.

M. Aapro, ESMO -Guidelines -Management of anaemia and iron deficiency in patients with cancer: Ann Oncol, 2018.

D. Sur,

, Collège National des Gynécologues et Obstétriciens Français, J Gynécologie Obstétrique Biol Reprod. sept, vol.34, issue.5, p.513, 2005.

N. Milman, Prepartum anaemia: prevention and treatment, Ann Hematol. déc, vol.87, issue.12, pp.949-59, 2008.

J. P. Peña-rosas and F. E. Viteri, Effects and safety of preventive oral iron or iron+folic acid supplementation for women during pregnancy, The Cochrane Collaboration

, Cochrane Database of Systematic Reviews

U. K. Chichester, , 2009.

D. Sur,

D. Broche, C. Gay, A. -. Branger, S. Grangeasse, L. Terzibachian et al., Anémies sévères du post-partum immédiat. Pratique clinique et intérêt du fer par voie intraveineuse, Gynécologie Obstétrique Fertil. juill, vol.32, issue.7-8, pp.613-622, 2004.

G. Groupe, , 2016.

S. A. Assemblée-générale-galenica, , vol.28, 2016.

D. Sur,

, Instruction DGOS/PF2/R3/DGS/PP2 n° 2014-32 du 24 fevrier 2014 relative aux modalités d'utilisation des spécialités à base de fer injectable, vol.24, 2014.

, Code de la santé publique -Article R5126-48. Code de la santé publique. 75. Décret n°2000-1316 du 26 décembre 2000 relatif aux pharmacies à usage intérieur et modifiant le code de la santé publique, SFPC. Référentiel -SFPC -Référentiel pharmacie hospitalière, 1316.

M. Auerbach and I. Macdougall, The available intravenous iron formulations: History, efficacy, and toxicology: The available intravenous iron formulations, Hemodial Int. avr, vol.21, 2017.

, HAS -Commission de transparence Fer carboxymaltose -Ferinject -juin, 2010.

M. Auerbach and H. Ballard, Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety, Hematology. 1 déc, vol.2010, issue.1, pp.338-385, 2010.

L. Sgismond, Carence martiale en réanimation diagnostic et traitement, Anesth Réanimation, vol.1, issue.4, pp.318-316, 2015.

J. Marx, Iron and infection: competition between host and microbes for a precious element, Best Pract Res Clin Haematol. juin, vol.15, issue.2, pp.411-437, 2002.

, Code de la santé publique -Article R5143-5-2 | Legifrance

D. Sur,

, ANSM. HAS -Commission de transparence -Venofer, ANSM. Fer saccharrose -Résumé des Caractéristiques du Produit, 2005.

D. Sur,

E. Universalis and . Colloïdes,

D. Sur,

B. G. Danielson, Structure, Chemistry, and Pharmacokinetics of Intravenous Iron Agents, J Am Soc Nephrol. 12 janv, vol.15, issue.2, pp.93-101, 2004.

C. W. Heath, M. B. Strauss, and W. B. Castle, QUANTITATIVE ASPECTS OF IRON DEFICIENCY IN HYPOCHROMIC ANEMIA, J Clin Invest, vol.11, issue.6, pp.1293-312, 1932.

I. C. Macdougall, EVOLUTION OF IV IRON COMPOUNDS OVER THE LAST CENTURY, J Ren Care. déc, vol.35, pp.8-13, 2009.

P. Geisser and S. Burckhardt, The Pharmacokinetics and Pharmacodynamics of Iron Preparations, Pharmaceutics. 4 janv, vol.3, issue.1, pp.12-33, 2011.

M. R. Jahn, H. B. Andreasen, S. Fütterer, T. Nawroth, V. Schünemann et al., A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications, Eur J Pharm Biopharm. août, vol.78, issue.3, pp.480-91, 2011.

R. W. Evans, R. Rafique, A. Zarea, C. Rapisarda, R. Cammack et al., Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera, JBIC J Biol Inorg Chem, vol.29, issue.1, pp.57-74, 2007.

, European Medicines Agency -Medicines under additional monitoring -List of medicines under additional monitoring

A. Carboxymaltose,

D. Sur,

B. Schaefer, P. Würtinger, A. Finkenstedt, V. Braithwaite, A. Viveiros et al., Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. Pantopoulos K, éditeur, PLOS ONE. 1 déc, vol.11, issue.12, p.167146, 2016.

S. Hardy and X. Vandemergel, Intravenous Iron Administration and Hypophosphatemia in Clinical Practice, Int J Rheumatol, vol.2015, pp.1-6, 2015.

Y. C. Fierz, Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient, EJCN, vol.3, 2014.

R. Evstatiev, P. Marteau, T. Iqbal, I. L. Khalif, J. Stein et al., Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease, Gastroenterology. sept, vol.141, issue.3, pp.846-853, 2011.

M. Vonesch, Etude de l'usage du fer injectable en établissement de santé et de son impact en terme d'économie hospitalière, Annales Pharmaceutiques Française. EMC, 2015.

J. E. Onken, D. B. Bregman, R. A. Harrington, D. Morris, J. Buerkert et al., Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial, Nephrol Dial Transplant. 1 avr, vol.29, issue.4, pp.833-875, 2014.

T. Steinmetz, B. Tschechne, O. Harlin, B. Klement, M. Franzem et al., Clinical experience with ferric carboxymaltose in the treatment of cancer-and chemotherapy-associated anaemia, Ann Oncol. févr, vol.24, issue.2, pp.475-82, 2013.

, ANNEXE Annexe 1 -Procédure de gestion de la carence martiale au CHU Grenoble Alpes -V1, 2018.